According to the US District Court for the Northern District of West Virginia, US, a Regeneron patent (#11,084,865) has been successfully defended for certain ophthalmic… Read More »Regeneron wins a patent ruling to extend Eylea protection but two other patents were deemed invalid.
Researchers at the University of Nevada, Reno School of Medicine and the Department of Ophthalmology, Weill Cornell Medical College, New York-Presbyterian Hospital, has published safety… Read More »Phase 1 study results published in the Lancet report stable vision following a single dose gene therapy encoding anti-VEGF protein.
Researchers at the Ottawa Hospital Research Institute, Ontario, Canada have reported a systematic review and meta-analysis on the safety and efficacy of adeno-associated viral (AAV)… Read More »A systematic review and meta-analysis of AAV treatments for several retinal degenerations report outcomes on safety and visual acuity.
by Dr. Gearóid Tuohy Dear EURETINA Members, Happy New Year ad a very warm welcome to the January 6th, 2024 edition of EURETINA’s web-based digital… Read More »January 6th, 2024 “EURETINA-Brief”© Issue No. 284
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved “Vabysmo”… Read More »Genentech (Roche Group) has reported approval from FDA for faricimab-svoa for the treatment of macular edema following Retinal Vein Occlusion (RVO).
Researchers at UCL and Moorfields Eye Hospital, UK, have reported clinical research using artificial intelligence (AI) tools to identify at-risk neonates of retinopathy of prematurity… Read More »Clinical research at UCL and Moorfields on AI tools to identify at-risk neonates of retinopathy of prematurity (ROP).
Researchers at the Herbert Wertheim School of Optometry and Vision Science, Science, University of California, Berkeley, have reported a rare type retinal output neurons called… Read More »Research studies of ON-type direction-selective ganglion cells may originate from some forms of nystagmus.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 19th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »December 19th, 2023 “EURETINA-Brief”© Issue No. 283
OliX Pharmaceuticals (KOSDAQ: 226950), based in Gyeonggi-do, Seoul, Republic of South Korea, has announced positive results from a phase 1 study evaluating the safety and… Read More »OliX Pharmaceuticals have announced positive results for an siRNA experimental treatment for AMD.
A recent update on phase 2 clinical research of a novel treatment for patients of Stargardt disease has reported a positive primary end-point slowing the… Read More »Clinical research on a novel oral therapy for Stargardt disease suggests uses a deuterated form of vitamin A.